Press releases
- Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
- Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
- Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
- Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
- Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
- Innovent Announces 2023 Annual Results and Business Updates
- Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
- Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024
- Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
- Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia
More ▼
Key statistics
On Friday, Innovent Biologics Inc (IVBXF:PKC) closed at 5.00, -22.00% below its 52-week high of 6.41, set on Nov 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.00 |
---|---|
High | 5.00 |
Low | 5.00 |
Bid | -- |
Offer | -- |
Previous close | 4.89 |
Average volume | 1.51k |
---|---|
Shares outstanding | 1.62bn |
Free float | 1.51bn |
P/E (TTM) | -- |
Market cap | 63.53bn HKD |
EPS (TTM) | -0.7047 HKD |
Data delayed at least 15 minutes, as of Apr 26 2024 20:06 BST.
More ▼